134 related articles for article (PubMed ID: 37897912)
41. Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells.
Pamarthy D; Behera SK; Swain S; Yadav S; Suresh S; Jain N; Bhadra MP
Drug Dev Res; 2023 Aug; 84(5):861-887. PubMed ID: 37070554
[TBL] [Abstract][Full Text] [Related]
42. The central role of glutathione peroxidase 4 in the regulation of ferroptosis and its implications for pro-inflammatory cytokine-mediated beta-cell death.
Krümmel B; Plötz T; Jörns A; Lenzen S; Mehmeti I
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166114. PubMed ID: 33662571
[TBL] [Abstract][Full Text] [Related]
43. Drug-induced lactate confers ferroptosis resistance via p38-SGK1-NEDD4L-dependent upregulation of GPX4 in NSCLC cells.
Cheng F; Dou J; Yang Y; Sun S; Chen R; Zhang Z; Wei H; Li J; Wu Z
Cell Death Discov; 2023 May; 9(1):165. PubMed ID: 37188685
[TBL] [Abstract][Full Text] [Related]
44. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
[No Abstract] [Full Text] [Related]
45. Targeting ferroptosis: Paving new roads for drug design and discovery.
Gu Y; Li Y; Wang J; Zhang L; Zhang J; Wang Y
Eur J Med Chem; 2023 Feb; 247():115015. PubMed ID: 36543035
[TBL] [Abstract][Full Text] [Related]
46. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
47. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib.
Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X
Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851
[TBL] [Abstract][Full Text] [Related]
48. Crystallization of VHL-based PROTAC-induced ternary complexes.
Wijaya AJ; Farnaby W; Ciulli A
Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
[TBL] [Abstract][Full Text] [Related]
49. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation.
Zhou C; Yu T; Zhu R; Lu J; Ouyang X; Zhang Z; Chen Q; Li J; Cui J; Jiang F; Jin KY; Sarapultsev A; Li F; Zhang G; Luo S; Hu D
Int J Biol Sci; 2023; 19(5):1471-1489. PubMed ID: 37056925
[TBL] [Abstract][Full Text] [Related]
50. Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy.
Sha R; Xu Y; Yuan C; Sheng X; Wu Z; Peng J; Wang Y; Lin Y; Zhou L; Xu S; Zhang J; Yin W; Lu J
EBioMedicine; 2021 Sep; 71():103560. PubMed ID: 34482070
[TBL] [Abstract][Full Text] [Related]
51. LncRNA OIP5-AS1 Knockdown Facilitated the Ferroptosis and Immune Evasion by Modulating the GPX4 in Oesophageal Carcinoma.
Hou J; Huang Q; Fan Z; Sang H; Wu S; Cheng S; Li Q
Comput Math Methods Med; 2022; 2022():8103198. PubMed ID: 35872956
[TBL] [Abstract][Full Text] [Related]
52. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
53. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
54. β-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer.
Zhao LP; Wang HJ; Hu D; Hu JH; Guan ZR; Yu LH; Jiang YP; Tang XQ; Zhou ZH; Xie T; Lou JS
J Adv Res; 2023 Sep; ():. PubMed ID: 37689240
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin.
Zhang X; Sui S; Wang L; Li H; Zhang L; Xu S; Zheng X
J Cell Physiol; 2020 Apr; 235(4):3425-3437. PubMed ID: 31556117
[TBL] [Abstract][Full Text] [Related]
56. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
57. ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy.
Yang S; Wong KH; Hua P; He C; Yu H; Shao D; Shi Z; Chen M
Acta Biomater; 2022 Mar; 140():492-505. PubMed ID: 34879292
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract][Full Text] [Related]
59. Dauricine alleviated secondary brain injury after intracerebral hemorrhage by upregulating GPX4 expression and inhibiting ferroptosis of nerve cells.
Peng C; Fu X; Wang K; Chen L; Luo B; Huang N; Luo Y; Chen W
Eur J Pharmacol; 2022 Jan; 914():174461. PubMed ID: 34469757
[TBL] [Abstract][Full Text] [Related]
60. Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS.
Han N; Li LG; Peng XC; Ma QL; Yang ZY; Wang XY; Li J; Li QR; Yu TT; Xu HZ; Xu X; Chen X; Wang MF; Li TF
Eur J Pharmacol; 2022 Mar; 919():174797. PubMed ID: 35122867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
